A Simplified Lung Ultrasound Guided Management Protocol Of Pulmonary Congestion in Hemodialysis - Trial NCT06296160
Access comprehensive clinical trial information for NCT06296160 through Pure Global AI's free database. This phase not specified trial is sponsored by Hamad Medical Corporation and is currently Recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hamad Medical Corporation
Timeline & Enrollment
N/A
May 28, 2023
May 22, 2024
Primary Outcome
Assess the effectiveness of adding B-line score evaluation through lung ultrasound to the standard of care to improve pulmonary congestion (measured by B lines score) in hemodialysis patients
Summary
Pulmonary congestion secondary to volume overload or interstitial tissue inflammation is
 common in chronic hemodialysis patients. This pulmonary congestion occurs mainly during the
 period between dialysis sessions and is an independent risk factor for cardiovascular event
 morbidity and mortality in this population. The evaluation of this pulmonary congestion and
 the estimation of the dry weight of hemodialysis patients according to conventional methods
 represent a real challenge for clinical nephrologists. Lung ultrasound is a new diagnostic
 approach validated in the assessment of pulmonary congestion. It would allow a better
 assessment of dry weight in chronic hemodialysis patients based on the results of preliminary
 studies, including our latest pilot study. However, there is little evidence comparing this
 novel approach to traditional approaches.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06296160
Non-Device Trial